Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Hydroxychloroquine, Abemaciclib and Endocrine Therapy in Hormone Receptor Positive (HR+)/Her 2 Negative Breast Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04316169
Recruitment Status : Not yet recruiting
First Posted : March 20, 2020
Last Update Posted : August 21, 2020
Sponsor:
Information provided by (Responsible Party):
Smitha Menon, Medical College of Wisconsin

Brief Summary:
The hypothesis is that abemaciclib synergizes with autophagy inhibitor hydroxychloroquine (HCQ/ Plaquenil), inducing apoptosis leading to tumor regression.

Condition or disease Intervention/treatment Phase
Solid Tumor Advanced Breast Cancer Drug: Abemaciclib Drug: Hydroxychloroquine 200 mg Drug: Faslodex Drug: Anastrazole Drug: Letrozole Drug: Hydroxychloroquine 400 mg Drug: Hydroxychloroquine 600 mg Phase 1

Detailed Description:

Part 1: 3+3 dose escalation of HCQ combined with abemaciclib in advanced solid tumors.

Part 2: HCQ at top-dose level from part one is combined with abemaciclib and endocrine therapy in HR+/Her 2- advanced breast cancer (ABC) and divided into two cohorts based on prior exposure to endocrine therapy.

Primary Objective

  1. Dose-escalation cohort: To determine safety and tolerability of HCQ combined with abemaciclib.
  2. Dose-expansion cohort: To determine safety and tolerability of HCQ combined with abemaciclib and endocrine therapy in HR+/Her2- ABC.

Secondary Objectives

  1. To assess the clinical efficacy of HCQ in combination with abemaciclib and hormone blockade in the dose- expansion cohort of advanced ER- positive breast cancer participants.
  2. To assess the clinical efficacy of HCQ in combination with abemaciclib in the dose- escalation cohort

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 44 participants
Allocation: Non-Randomized
Intervention Model: Sequential Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Hydroxychloroquine (HCQ) in Combination With Abemaciclib and Endocrine Therapy in HR+/Her 2- Advanced Breast Cancer After a Lead in Dose Escalation Cohort of HCQ and Abemaciclib in Advanced Solid Tumors
Estimated Study Start Date : July 2021
Estimated Primary Completion Date : July 2024
Estimated Study Completion Date : July 2025

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Breast Cancer

Arm Intervention/treatment
Experimental: Abemaciclib and HCQ 200 mg b.i.d.
HCQ will have a dose escalation of a 3 + 3 design.
Drug: Abemaciclib
150 mg b.i.d
Other Name: Verzenio

Drug: Hydroxychloroquine 200 mg
Dose level: 200 mg b.i.d.
Other Name: Plaquenil

Experimental: Abemaciclib and HCQ 400 mg b.i.d.
HCQ will have a dose escalation of a 3 + 3 design.
Drug: Abemaciclib
150 mg b.i.d
Other Name: Verzenio

Drug: Hydroxychloroquine 400 mg
Dose level: 400 mg. b.i.d.
Other Name: Plaquenil

Experimental: Abemaciclib and HCQ 600 mg b.i.d.
HCQ will have a dose escalation of a 3 + 3 design.
Drug: Abemaciclib
150 mg b.i.d
Other Name: Verzenio

Drug: Hydroxychloroquine 600 mg
Dose level: 600 mg b.i.d.
Other Name: Plaquenil

Experimental: Abemaciclib + HCQ (Optimal Dose) + endocrine therapy

This group will be divided into two cohorts:

  1. eligible participants who are endocrine therapy naive.
  2. eligible participants who had one prior line of endocrine therapy.
Drug: Abemaciclib
150 mg b.i.d
Other Name: Verzenio

Drug: Hydroxychloroquine 200 mg
Dose level: 200 mg b.i.d.
Other Name: Plaquenil

Drug: Faslodex
Cohort B will receive Faslodex.
Other Name: Fulvestrant

Drug: Anastrazole
Cohort A will receive anastrazole or letrozole.
Other Name: Arimidex

Drug: Letrozole
Cohort A will receive anastrazole or letrozole.
Other Name: Femara

Drug: Hydroxychloroquine 400 mg
Dose level: 400 mg. b.i.d.
Other Name: Plaquenil

Drug: Hydroxychloroquine 600 mg
Dose level: 600 mg b.i.d.
Other Name: Plaquenil




Primary Outcome Measures :
  1. Dose-limiting toxicities during dose-escalation phase. [ Time Frame: 28 days for each cohort ]
    The number of participants with dose-limiting toxicities during the dose-escalation phase (HCQ in combination with abemaciclib).

  2. Dose-limiting toxicities in dose-expansion phase. [ Time Frame: 28 days for each cohort ]
    The number of participants with dose-limiting toxicities during the dose-expansion phase (maximum-tolerated dose of HCQ and abemaciclib in combination with endocrine therapy.


Secondary Outcome Measures :
  1. Progression-free survival. [ Time Frame: 1 Year ]
    This measure is the number of months participants remain free from evidence of disease. Participants will undergo imaging every eight weeks and results will be reported annually.

  2. Overall response rate. [ Time Frame: 1 Year ]
    The number of participants who have a partial or complete response based on tumor measurement by CT or MRI using RECIST 1.1. Participants will be imaged every eight weeks and reported annually.

  3. Clinical benefit rate. [ Time Frame: 1 Year ]
    The percentage of participants who have a complete response, partial response and stable disease as measurement by CT or MRI using RECIST 1.1. Participants will be imaged every eight weeks and reported annually.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria for Dose-escalation Phase

  1. Participants (men and women) with advanced or metastatic cancers who are refractory to standard therapy, relapsed after standard therapy, or who have no standard therapy available that improves progression-free or overall survival by at least three months.
  2. Intact G1/S checkpoint in tumor tissue defined by positive-Rb staining and negative-low-molecule weight isoforms of cyclin E (LMWE) with staining done on formalin-fixed paraffin embedded slides from archival tissue or cell blocks.
  3. Demonstrate measurable disease as defined by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criterion.
  4. Age ≥ 18 years.
  5. Estimated life expectancy of three months.
  6. Eastern Cooperative Oncology Group (ECOG) performance status ≤2.
  7. Participants who received chemotherapy must have recovered (Common Terminology Criteria for Adverse Events (CTCAE) Grade ≤1) from the acute effects of chemotherapy except for residual alopecia or Grade 2 peripheral neuropathy prior to randomization. A washout period of at least 21 days is required between the last chemotherapy dose and the first dose of the study drug/s (provided the participant did not receive radiotherapy).
  8. Participants who received palliative radiotherapy must have completed and fully recovered from the acute effects of radiotherapy. A washout period of at least 14 days is required between the end of radiotherapy and the first dose of the study drug/s.
  9. Participants must be >/= 3 weeks from major surgery. For biologic/targeted agents, participants must be >/= 5 half-lives or >/= 3 weeks from the last dose (whichever comes first).
  10. The participant is able to swallow oral medications.
  11. Documented ophthalmic exam within the last 12 months demonstrating no evidence of retinopathy. Participants with retinal changes will be considered for enrollment with written clearance from a board-certified ophthalmologist.
  12. The participant must sign informed consent prior to registration.
  13. The participant has adequate organ function for all of the following criteria, as defined in below.

    Hematologic:

    Absolute Neutrophil Count (ANC) >/=1.5 × 10^9/L Platelets: >/=100 × 10^9/L Hemoglobin: >/= 8 g/dL Participants may receive erythrocyte transfusions to achieve this hemoglobin level at the discretion of the investigator. Initial treatment must not begin earlier than the day after the erythrocyte transfusion.

    Hepatic:

    Total bilirubin: ≤ 1.5 × upper limit of normal (ULN) Participants with Gilbert's syndrome with a total bilirubin ≤ 2 times ULN and direct bilirubin within normal limits are permitted.

    Alanine Aminotransferase (ALT) and aspartate aminotransferase (AST): ≤ 3 × ULN Renal Serum creatinine: ≤ 1.5 × ULN

  14. Female participants must meet one of the following:

    • Postmenopausal for at least one year before enrollment, OR
    • Surgically sterile (i.e., undergone a hysterectomy or bilateral oophorectomy), OR
    • If participant is of childbearing potential (defined as not satisfying either of the above two criteria), agrees to practice two acceptable methods of contraception (combination methods require use of two of the following: diaphragm with spermicide, cervical cap with spermicide, contraceptive sponge, male or female condom, hormonal contraceptive) from the time of signing of the informed consent form through 21 days after the last dose of study agent, OR o Agrees to practice true abstinence when this is in line with the preferred and usual lifestyle of the participant. (Periodic abstinence [e.g., calendar, ovulation, symptothermal, postovulation methods] and withdrawal are not acceptable contraception methods.)
  15. Male participants, even if surgically sterilized (i.e., status postvasectomy), must agree to one of the following:

    • Practice effective barrier contraception during the entire study period and through 60 calendar days after the last dose of study agent, OR o Agree to practice true abstinence when this is in line with the preferred and usual lifestyle of the participant. (Periodic abstinence [e.g., calendar, ovulation, symptothermal, post ovulation methods] and withdrawal are not acceptable methods of contraception.)

Exclusion Criteria for Dose-escalation Phase

  1. Serious concomitant systemic disorder that would compromise the safety of the participant or compromise the participant's ability to complete the study, as determined by the treating physician or the principal investigator (for example, interstitial lung disease, severe dyspnea at rest, history of major surgical resection involving the stomach or small bowel, or preexisting Crohn's disease or ulcerative colitis or a preexisting chronic condition resulting in baseline grade 2 or higher diarrhea).
  2. Second primary malignancy except most in situ carcinomas (e.g., adequately treated non-melanomatous carcinoma of the skin) or other malignancy treated at least five years previously with no evidence of recurrence.
  3. Uncontrolled or symptomatic central nervous system (CNS) metastases.
  4. Known history of glucose-6-phosphate dehydrogenase (G6PD) deficiency.
  5. Taking other commercially available medications, which may theoretically either stimulate or inhibit autophagy; these include calcitriol and chloroquine.
  6. Taking medications which may lead to interactions with HCQ, including penicillamine, telbivudine, botulinum toxin, digoxin and propafenone.
  7. Must not be taking HCQ at baseline.
  8. Females who are pregnant or lactating.
  9. The participant has a history of active bacterial infection (requiring intravenous [IV] antibiotics at time of initiating study treatment), fungal infection or detectable viral infection (such as known human immunodeficiency virus positivity or with known active hepatitis B or C [for example, hepatitis B surface antigen positive]. Screening tests are NOT required for this criterion.
  10. The participant has a personal history of any of the following conditions: syncope of cardiovascular etiology, ventricular arrhythmia of pathological origin (including, but not limited to, ventricular tachycardia and ventricular fibrillation), or sudden cardiac arrest.
  11. Participant receiving treatment with strong and moderate Cytochrome P450, family 3, subfamily A (CYP3A) inducers within seven days prior to the first dose of study drugs.
  12. Participant receiving treatment with tamoxifen within seven days prior to the first dose of study drugs.
  13. Participant receiving treatment with live vaccines within 30 days prior to the first dose of study drugs.
  14. Participant receiving medications which may prolong the QT interval.

Eligibility criteria- Part 2 (Enrollment criteria for the dose-expansion phase)

Inclusion Criteria

  1. Postmenopausal women with HR+/ Her2- advanced breast cancer with endocrine naïve disease will be enrolled in Cohort A. Endocrine naïve participants are defined as advanced breast cancer participants eligible for first-line aromatase inhibitor in combination with cyclin-dependent kinase 4 / 6 (CDK4 / 6) inhibitor therapy. Prior endocrine therapy in the neoadjuvant or adjuvant setting is permitted if the participant had a disease-free interval of more than 12 months.
  2. Postmenopausal women with HR +/ Her 2 -advanced breast cancer with endocrine pretreated disease will be enrolled in Cohort B. Endocrine pretreated participants are defined as advanced breast cancer participants who progressed while receiving endocrine therapy as first-line therapy or who had prior endocrine therapy in the neoadjuvant or adjuvant setting with a disease-free interval of less than 12 months and who are otherwise eligible to receive a combination of Faslodex® and CDK 4/6 inhibitor may be enrolled in Cohort B.
  3. Intact G1/S checkpoint in tumor tissue defined by positive-Rb staining and negative-low-molecule weight isoforms of cyclin E (LMWE) with staining done on formalin-fixed paraffin embedded slides from archival tissue or cell blocks.
  4. Age ≥ 18 years.
  5. Peri or premenopausal women may be enrolled in Cohort A or B, if they are receiving a gonadotropin-releasing agonist and meet eligibility criteria as above for postmenopausal women.
  6. Female participants must meet one of the following:

    • Postmenopausal for at least one year before enrollment, OR
    • Surgically sterile (i.e., undergone a hysterectomy or bilateral oophorectomy), OR
    • If participant is of childbearing potential (defined as not satisfying either of the above two criteria), agrees to practice two acceptable methods of contraception (combination methods requires use of two of the following: diaphragm with spermicide, cervical cap with spermicide, contraceptive sponge, male or female condom, hormonal contraceptive) from the time of signing of the informed consent form through 21 days after the last dose of study agent, OR o Agree to practice true abstinence when this is in line with the preferred and usual lifestyle of the participant. (Periodic abstinence [e.g., calendar, ovulation, symptothermal, postovulation methods] and withdrawal are not acceptable contraception methods.)
  7. Estimated life expectancy of at least six months.
  8. ECOG performance status ≤2.
  9. Demonstrates measurable disease as defined by RECIST 1.1 criteria or non-measurable bone-only disease.
  10. Documented ophthalmic exam within the last 12 months demonstrating no evidence of retinopathy. Participants with retinal changes will be considered for enrollment with written clearance from a board-certified ophthalmologist.
  11. Must sign informed consent prior to registration.
  12. The participant has adequate organ function for all of the following criteria, as defined below.

    Hematologic:

    Absolute Neutrophil Count (ANC) >/=1.5 × 10^9/L Platelets: >/=100 × 10^9/L Hemoglobin: >/= 8 g/dL Participants may receive erythrocyte transfusions to achieve this hemoglobin level at the discretion of the investigator. Initial treatment must not begin earlier than the day after the erythrocyte transfusion.

    Hepatic:

    Total bilirubin: ≤ 1.5 × upper limit of normal (ULN) Participants with Gilbert's syndrome with a total bilirubin ≤ 2 times ULN and direct bilirubin within normal limits are permitted.

    Alanine Aminotransferase (ALT) and aspartate aminotransferase (AST): ≤ 3 × ULN Renal Serum creatinine: ≤ 1.5 × ULN

  13. Participants who previously received chemotherapy must have recovered (Common Terminology Criteria for Adverse Events (CTCAE) grade ≤1) from the acute effects of chemotherapy except for residual alopecia or grade 2 peripheral neuropathy prior to randomization. A washout period of at least 21 days is required between last chemotherapy dose and first dose of the study drug/s (provided the participant did not receive radiotherapy).
  14. Participants who received palliative radiotherapy must have completed and fully recovered from the acute effects of radiotherapy. A washout period of at least 14 days is required between end of palliative radiotherapy and first dose of the study drug/s.
  15. The participant is able to swallow oral medications.

Exclusion Criteria

  1. Presence of visceral crisis, lymphangitic spread, leptomeningeal carcinomatosis or inflammatory breast cancer.
  2. Prior therapy with a CDK4/6 inhibitor.
  3. Serious concomitant systemic disorder that would compromise the safety of the participant or compromise the participant's ability to complete the study, as determined by the treating physician or the principal investigator (for example, interstitial lung disease, severe dyspnea at rest, history of major surgical resection involving the stomach or small bowel, or preexisting Crohn's disease or ulcerative colitis or a preexisting chronic condition resulting in baseline grade 2 or higher diarrhea).
  4. Second primary malignancy except most in situ carcinoma (e.g., adequately treated non-melanomatous carcinoma of the skin) or other malignancy treated at least five years previously with no evidence of recurrence.
  5. Uncontrolled or symptomatic CNS metastases.
  6. Known history of G6PD deficiency.
  7. Taking other commercially available medications which may theoretically either stimulate or inhibit autophagy; these include calcitriol and chloroquine.
  8. Taking medications which may lead to interactions with HCQ, including penicillamine, telbivudine, botulinum toxin, digoxin, and propafenone.
  9. Must not be taking HCQ at baseline.
  10. Females who are pregnant or lactating.
  11. The participants has active bacterial infection (requiring intravenous [IV] antibiotics at time of initiating study treatment), fungal infection, or detectable viral infection (such as known human immunodeficiency virus positivity or with known active hepatitis B or C [for example, hepatitis B surface antigen positive]). No screening tests is required for this criterion.
  12. The participant has a personal history of any of the following conditions: syncope of cardiovascular etiology, ventricular arrhythmia of pathological origin (including, but not limited to, ventricular tachycardia and ventricular fibrillation), or sudden cardiac arrest.
  13. The participant receiving treatment with strong and moderate CYP3A inducers within seven days prior to the first dose of study drugs.
  14. Participant receiving treatment with tamoxifen within seven days prior to the first dose of study drugs.
  15. Participant receiving treatment with live vaccines within 30 days prior to the first dose of study drugs.
  16. Participant receiving medications which may prolong the QT interval.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04316169


Contacts
Layout table for location contacts
Contact: Medical College of Wisconsin Cancer Center Clinical Trials Office 414-805-8900 cccto@mcw.edu

Locations
Layout table for location information
United States, Wisconsin
Froedtert Hospital and the Medical College of Wisconsin
Milwaukee, Wisconsin, United States, 53226
Contact: Froedtert Hospital and the Medical College of Wisconsin    866-680-0505 ext 8900    cccto@mcw.edu   
Sponsors and Collaborators
Medical College of Wisconsin
Investigators
Layout table for investigator information
Principal Investigator: Smitha Menon, MD Medical College of Wisconsin
Layout table for additonal information
Responsible Party: Smitha Menon, Associate Professor, Medical College of Wisconsin
ClinicalTrials.gov Identifier: NCT04316169    
Other Study ID Numbers: PRO00035701
First Posted: March 20, 2020    Key Record Dates
Last Update Posted: August 21, 2020
Last Verified: August 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: Yes
Additional relevant MeSH terms:
Layout table for MeSH terms
Breast Neoplasms
Neoplasms by Site
Neoplasms
Breast Diseases
Skin Diseases
Hydroxychloroquine
Letrozole
Fulvestrant
Anastrozole
Antineoplastic Agents
Aromatase Inhibitors
Steroid Synthesis Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Estrogen Antagonists
Hormone Antagonists
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs
Antimalarials
Antiprotozoal Agents
Antiparasitic Agents
Anti-Infective Agents
Antirheumatic Agents
Antineoplastic Agents, Hormonal
Estrogen Receptor Antagonists